Author
J G Castaño
Bio: J G Castaño is an academic researcher. The author has contributed to research in topics: Phosphofructokinase & Glycogen phosphorylase. The author has an hindex of 1, co-authored 1 publications receiving 121 citations.
Papers
More filters
TL;DR: Phosphofructokinase inactivation by glucagon parallels the known inactivation of pyruvate kinase L and activation of glycogen phosphorylase alpha and exogenous cyclic AMP mimics the effect of this hormone.
124 citations
Cited by
More filters
TL;DR: As a counterregulatory hormone for insulin, glucagon plays a critical role in maintaining glucose homeostasis in vivo in both animals and humans and has been pursued extensively in recent years as potential targets for the therapeutic treatment of diabetes.
Abstract: As a counterregulatory hormone for insulin, glucagon plays a critical role in maintaining glucose homeostasis in vivo in both animals and humans. To increase blood glucose, glucagon promotes hepatic glucose output by increasing glycogenolysis and gluconeogenesis and by decreasing glycogenesis and glycolysis in a concerted fashion via multiple mechanisms. Compared with healthy subjects, diabetic patients and animals have abnormal secretion of not only insulin but also glucagon. Hyperglucagonemia and altered insulin-to-glucagon ratios play important roles in initiating and maintaining pathological hyperglycemic states. Not surprisingly, glucagon and glucagon receptor have been pursued extensively in recent years as potential targets for the therapeutic treatment of diabetes.
797 citations
TL;DR: The alteration in hepatic and skeletal muscle glycogen content and hepatic glucokinase, hexokinase and glucose-6-phosphate and phosphofructokinase levels in diabetic mice were partially restored by EJ but not by TC, and the mechanism of action of EJ and TC is discussed.
433 citations
TL;DR: Fru-2,6-P2 is not an intermediary metabolite of glycolysis, but its most potent regulator and its potential role in the control of metabolism in various organisms is delineated.
Abstract: It was in 1909 that Young, in the laboratory of Harden, isolated from fermenting yeast the fructose bisphosphate (the Harden and Young ester) that was later identified by Levene & Raymond (1928) as fructose 1,6-bisphosphate. Some 71 years elapsed until a second fructose bisphosphate was isolated from living cells and identified as fructose 2,6bisphosphate (Van Schaftingen et al., 1980c). In contrast with its elder brother, Fru-2,6-P2 is not an intermediary metabolite of glycolysis, but its most potent regulator. In the present review, we will summarize the work that led to its discovery and we will try to delineate its potential role in the control of metabolism in various organisms.
396 citations
293 citations
TL;DR: The low-molecular-weight stimulator of phosphofructokinase has been purified from rat liver and is tentatively identified as fructose 2,6-bisphosphate.
Abstract: The low-molecular-weight stimulator of phosphofructokinase [Van Schaftingen, Hue & Hers (1980) Biochem. J. 192, 887-895] has been purified from rat liver. It was completely destroyed upon incubation with 0.01 M-HCl for 10 min at 20 degrees C and fructose 6-phosphate and a reducing power equivalent in amount to the acid-labile organic phosphate were formed. It was therefore tentatively identified as fructose 2,6-bisphosphate.
292 citations